Log in

Relevant bibliographies by topics / Platinum group. Antineoplastic agents / Journal articles

To see the other types of publications on this topic, follow the link: Platinum group. Antineoplastic agents.

Journal articles on the topic 'Platinum group. Antineoplastic agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Platinum group. Antineoplastic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Odularu, Ayodele T., Peter A. Ajibade, Johannes Z. Mbese, and Opeoluwa O. Oyedeji. "Developments in Platinum-Group Metals as Dual Antibacterial and Anticancer Agents." Journal of Chemistry 2019 (November 6, 2019): 1–18. http://dx.doi.org/10.1155/2019/5459461.

Full text

Abstract:

Platinum-group (PG) complexes have been used as antibacterial and anticancer agents since the discovery of cisplatin. The science world still requires improvement on these complexes because of multidrug and antineoplastic resistances. This review observes discoverers and history of these platinum-group metals (PGMs), as well as their beneficial applications. The focus of this study was biological applications of PGMs in relation to human health. Sandwich and half-sandwich PGM coordination compounds and their metal nanoparticles give improved results for biological activities by enhancing effic

APA, Harvard, Vancouver, ISO, and other styles

2

César, Bruno Nogueira, and Marcelino de Souza Durão Júnior. "Acute kidney injury in cancer patients." Revista da Associação Médica Brasileira 66, suppl 1 (2020): s25—s30. http://dx.doi.org/10.1590/1806-9282.66.s1.25.

Full text

Abstract:

SUMMARY The increasing prevalence of neoplasias is associated with new clinical challenges, one of which is acute kidney injury (AKI). In addition to possibly constituting a clinical emergency, kidney failure significantly interferes with the choice and continuation of antineoplastic therapy, with prognostic implications in cancer patients. Some types of neoplasia are more susceptible to AKI, such as multiple myeloma and renal carcinoma. In cancer patients, AKI can be divided into pre-renal, renal (intrinsic), and post-renal. Conventional platinum-based chemotherapy and new targeted therapy ag

APA, Harvard, Vancouver, ISO, and other styles

3

Azab, Belal, Anood Alassaf, Abdulrahman Abu-Humdan, et al. "Genotoxicity of cisplatin and carboplatin in cultured human lymphocytes: a comparative study." Interdisciplinary Toxicology 12, no. 2 (2019): 93–97. http://dx.doi.org/10.2478/intox-2019-0011.

Full text

Abstract:

Abstract Cisplatin and carboplatin are integral parts of many antineoplastic management regimens. Both platinum analogues are potent DNA alkylating agents that robustly induce genomic instability and promote apoptosis in tumor cells. Although the mechanism of action of both drugs is similar, cisplatin appears to be more cytotoxic. In this study, the genotoxic potential of cisplatin and carboplatin was compared using chromosomal aberrations (CAs) and sister-chromatid exchange (SCE) assays in cultured human lymphocytes. Results showed that cisplatin and carboplatin induced a significant increase

APA, Harvard, Vancouver, ISO, and other styles

4

Li, Lu, Sheng Nie, Chen Ren, Yanqin Li, and Dehua Wu. "The incidence, risk factors and outcomes of chemotherapy related acute kidney injury in China." Journal of Clinical Oncology 38, no. 15_suppl (2020): e24161-e24161. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e24161.

Full text

Abstract:

e24161 Background: Nephrotoxicity of chemotherapeutic agents remains a significant complication limiting the efficacy of the treatment. However, comprehensive data on the epidemiology and outcomes of chemotherapy related acute kidney Injury in China is lacking. Methods: We conducted a nationwide cohort study of hospitalized patients from 25 general and children’s hospitals in China during 2013-2015. Patient-level data were obtained from the electronic hospitalization information system, prescription database and laboratory databases of all cancer patients who received chemotherapy and had at l

APA, Harvard, Vancouver, ISO, and other styles

5

Bakalova, Adriana G., Rossen T. Buyukliev, Rositsa P. Nikolova, Boris L. Shivachev, Rositsa A. Mihaylova, and Spiro M. Konstantinov. "Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin." Anti-Cancer Agents in Medicinal Chemistry 19, no. 10 (2019): 1243–52. http://dx.doi.org/10.2174/1871520619666190214103345.

Full text

Abstract:

Background: The accidental discovery of Cisplatin’s growth-inhibiting properties a few decades ago led to the resurgence of interest in metal-based chemotherapeutics. A number of well-discussed factors such as severe systemic toxicity and unfavourable physicochemical properties further limit the clinical application of the platinating agents. Great efforts have been undertaken in the development of alternative platinum derivatives with an extended antitumor spectrum and amended toxicity profile as compared to the reference drug cisplatin. The rational design of conventional platinum analogues

APA, Harvard, Vancouver, ISO, and other styles

6

Markman, Maurie. "Toxicities of the platinum antineoplastic agents." Expert Opinion on Drug Safety 2, no. 6 (2003): 597–607. http://dx.doi.org/10.1517/14740338.2.6.597.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Makrilia, Nektaria, Ekaterini Syrigou, Ioannis Kaklamanos, Leonidas Manolopoulos, and Muhammad Wasif Saif. "Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review." Metal-Based Drugs 2010 (September 20, 2010): 1–11. http://dx.doi.org/10.1155/2010/207084.

Full text

Abstract:

Platinum-containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been approved in the first-line setting of numerous malignancies, such as ovarian, bladder, head and neck, colorectal, and lung cancer. Their extensive use over the last decade has led to a significant increase in the incidence of hypersensitivity reactions, which are defined as unforeseen reactions whose signs and symptoms cannot be explained by the known toxicity of these drugs. Skin rash, flushing, abdominal cramping, itchy palms, and back pain are common symptoms. Cardiovascular and respiratory complications

APA, Harvard, Vancouver, ISO, and other styles

8

Fanelli, Mirco, Mauro Formica, Vieri Fusi, Luca Giorgi, Mauro Micheloni, and Paola Paoli. "New trends in platinum and palladium complexes as antineoplastic agents." Coordination Chemistry Reviews 310 (March 2016): 41–79. http://dx.doi.org/10.1016/j.ccr.2015.11.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bakhonsky, Vladyslav V., Aleksander A. Pashenko, Jonathan Becker, et al. "Synthesis and antiproliferative activity of hindered, chiral 1,2-diaminodiamantane platinum(ii) complexes." Dalton Transactions 49, no. 40 (2020): 14009–16. http://dx.doi.org/10.1039/d0dt02391d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fortner, Clarence L., and Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 1 (1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Full text

Abstract:

Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information

APA, Harvard, Vancouver, ISO, and other styles

11

Zajączkowska, Renata, Magdalena Kocot-Kępska, Wojciech Leppert, Anna Wrzosek, Joanna Mika, and Jerzy Wordliczek. "Mechanisms of Chemotherapy-Induced Peripheral Neuropathy." International Journal of Molecular Sciences 20, no. 6 (2019): 1451. http://dx.doi.org/10.3390/ijms20061451.

Full text

Abstract:

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating t

APA, Harvard, Vancouver, ISO, and other styles

12

De Almeida, Mauro, Ana Fontes, Richard Berg, Eloi César, Emanoel De Castro Antunes Felício, and José De Souza Filho. "Synthesis of Platinum Complexes from N-Benzyl-1,3-Propanediamine Derivatives, Potential Antineoplastic Agents." Molecules 7, no. 4 (2002): 405–11. http://dx.doi.org/10.3390/70400405.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hall, Amy L., Paul A. Demers, George Astrakianakis, Calvin Ge, and Cheryl E. Peters. "Estimating National-Level Exposure to Antineoplastic Agents in the Workplace: CAREX Canada Findings and Future Research Needs." Annals of Work Exposures and Health 61, no. 6 (2017): 656–58. http://dx.doi.org/10.1093/annweh/wxx042.

Full text

Abstract:

AbstractObjectives:Occupational exposure to antineoplastic agents occurs in various environments and is associated with increased cancer risk and adverse reproductive outcomes. National-level information describing the location and extent of occupational exposure to antineoplastic agents is unavailable in Canada and most other countries. CAREX Canada aimed to estimate the prevalence and relative levels of occupational exposures to antineoplastic agents across work setting, occupation, and sex.Methods:‘Exposure’ was defined as any potential for worker contact with antineoplastic agents. Baselin

APA, Harvard, Vancouver, ISO, and other styles

14

Amir, Eitan, Bostjan Seruga, Joaquin Martinez-Lopez, et al. "Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs." Journal of Clinical Oncology 29, no. 18 (2011): 2543–49. http://dx.doi.org/10.1200/jco.2011.35.2393.

Full text

Abstract:

Purpose The relationship between market pricing of new anticancer drugs and the magnitude of clinical benefit caused by them has not been reported. Patients and Methods Randomized clinical trials (RCTs) that evaluated approved new agents for solid tumors by the US Food and Drug administration since the year 2000 were assessed. Hazard ratios (HRs) and 95% CIs were extracted for time-to-event end points described for each RCT. HRs were pooled for three groups: agents directed against a specific molecular target, for which the target population is selected by a biomarker (group A); less specific

APA, Harvard, Vancouver, ISO, and other styles

15

Kushev, Daniel N., Nadejda C. Spassovska, Svetoslav I. Taxirov, and Konstantin C. Grancharov. "Cytotoxicity and Antitumor Activity of Platinum(II) Complexes of Aromatic and Cycloalkanecarboxylic Acid Hydrazides." Zeitschrift für Naturforschung C 52, no. 1-2 (1997): 49–54. http://dx.doi.org/10.1515/znc-1997-1-209.

Full text

Abstract:

AbstractNew platinum(II) complexes of cyclohexanecarboxylic acid hydrazide (chcah) were synthesized and characterized by elemental analysis, IR. and 1H NMR spectra. Their inhibitory effects on cell growth and macromolecular synthesis of Friend leukemia cells in culture as well as the in vivo antitumor activity towards L1210 leukemia in mice were compared with those of complexes containing differently substituted aromatic acid hydrazides. Some of the complexes exhibited antineoplastic activity. No correlation between the in vitro cytotoxicity and the in vivo antitumor activity was found. Howeve

APA, Harvard, Vancouver, ISO, and other styles

16

Schweer, David, J. Robert McCorkle, Jurgen Rohr, Oleg V. Tsodikov, Frederick Ueland, and Jill Kolesar. "Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer." Biomedicines 9, no. 1 (2021): 70. http://dx.doi.org/10.3390/biomedicines9010070.

Full text

Abstract:

Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-r

APA, Harvard, Vancouver, ISO, and other styles

17

Donnelly, Erling T., Yanfeng Liu, and Sara Rockwell. "Efaproxiral (RSR13) Plus Oxygen Breathing Increases the Therapeutic Ratio of Carboplatin in EMT6 Mouse Mammary Tumors." Experimental Biology and Medicine 231, no. 3 (2006): 317–21. http://dx.doi.org/10.1177/153537020623100312.

Full text

Abstract:

Carboplatin, a member of the platinum family of alkylating agents, is often used in combination with radiotherapy. Some studies, including a recent publication from our laboratory, have suggested that the cytotoxic effects of platinum compounds may be altered by changes in the post-treatment oxygenation. The study reported here assessed whether post-treatment changes in tumor oxygenation caused by oxygen breathing alone or in combination with efaproxiral (RSR13) altered the effects of carboplatin. Efaproxiral, which allosterically modifies hemoglobin-oxygen binding to increase tumor pO2, has b

APA, Harvard, Vancouver, ISO, and other styles

18

Pažout, Richard, Jaroslav Maixner, Michaela Hrdá, Tereza Loužilová, and Petr Kačer. "A bromine analogue of picoplatin: a new substance from the group of platinum-based chemotherapeutics." Acta Crystallographica Section C Crystal Structure Communications 69, no. 4 (2013): 337–39. http://dx.doi.org/10.1107/s0108270113004708.

Full text

Abstract:

A new substance,cis-amminedibromido(2-methylpyridine-κN)platinum(II),cis-[PtBr2(C6H7N)(NH3)], which is a potential platinum-based antineoplastic agent for the treatment of patients with solid tumors, has been synthesized and structurally characterized. There is one molecule in the asymmetric unit and molecules are linkedviatwo symmetry-independent N—H...Br hydrogen bonds into zigzag chains running parallel to thecaxis. C—H...Br hydrogen bonds crosslink these chains to give a layer parallel to (010). N—H...Br hydrogen bonds and π–π stacking interactions between pairs of pyridine rings stack the

APA, Harvard, Vancouver, ISO, and other styles

19

Mountzios, Giannis, Aspasia Soultati, Dimitrios Pectasides, Meletios A. Dimopoulos, and Christos A. Papadimitriou. "Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents." Obstetrics and Gynecology International 2013 (2013): 1–8. http://dx.doi.org/10.1155/2013/536765.

Full text

Abstract:

Despite the available prevention and early detection strategies, squamous-cell carcinoma of the uterine cervix is still diagnosed as locally advanced disease in a considerable proportion of patients. As a potent sensitizer of cancer cells, cisplatin has been the “traditional partner” of external beam irradiation in this setting for more than two decades. Induction chemotherapy strategies followed by concurrent chemoradiation or surgery and preoperative concurrent chemoradiation have been recently implemented in clinical trials in an effort to optimize local control and to minimize the risk of

APA, Harvard, Vancouver, ISO, and other styles

20

Maiese, Eric M., Bruno Émond, Jinan Liu, et al. "Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States." Journal of Clinical Oncology 39, no. 15_suppl (2021): e18693-e18693. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18693.

Full text

Abstract:

e18693 Background: Among patients (pts) with endometrial cancer (EC), response rates for platinum-based regimens in the first-line (1L) setting range from 40% to 62% in clinical trials. This study describes patient characteristics, treatment patterns, time to next treatment (TTNT), and overall survival (OS) among pts with advanced/recurrent EC treated with a platinum-based regimen in a real-world setting in the US. Methods: This retrospective study used Optum Clinformatics Extended Data Mart de-identified databases from January 1, 2007, to December 31, 2019. Adult pts with advanced/recurrent E

APA, Harvard, Vancouver, ISO, and other styles

21

Liu, Jinan, Eric M. Maiese, Bruno Émond, et al. "Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States." Journal of Clinical Oncology 39, no. 28_suppl (2021): 291. http://dx.doi.org/10.1200/jco.2020.39.28_suppl.291.

Full text

Abstract:

291 Background: Among patients (pts) with endometrial cancer (EC), response rates for platinum-based regimens in the first-line (1L) setting range from 40% to 62% in clinical trials. This study describes patient characteristics, treatment patterns, time to next treatment (TTNT), and overall survival (OS) among pts with advanced/recurrent EC treated with a platinum-based regimen in a real-world setting in the US. Methods: This retrospective study used Optum Clinformatics Extended Data Mart de-identified databases from January 1, 2007, to December 31, 2019. Adult pts with advanced/recurrent EC w

APA, Harvard, Vancouver, ISO, and other styles

22

Toffoli, Giuseppe, Alessandra Viel, Loretta Tumiotto, Patrizio Buttazzi, Gabriella Biscontin, and Mauro Boiocchi. "Sensitivity Pattern of Normal and Ha-Ras Transformed Nih3T3 Fibroblasts to Antineoplastic Drugs." Tumori Journal 75, no. 5 (1989): 423–28. http://dx.doi.org/10.1177/030089168907500505.

Full text

Abstract:

Ha-ras-transformed NIH3T3 fibroblasts were compared with the parental cell line to investigate the influence of the Ha-ras oncogene on cellular chemosensitivity to antineoplastic drugs. Four NIH3T3 cell clones independently transformed by the Ha-ras oncogene, activated by mutation or overexpression, were analyzed: 3 clones were obtained by transfection of NIH3T3 cells with a mutation-activated Ha-ras gene and 1 clone by transfection of a large copy number of the normal Ha-ras protooncogene. Chemosensitivity of the transformed clones and of the parental cell line was analyzed when cells were in

APA, Harvard, Vancouver, ISO, and other styles

23

Szwamel, Katarzyna, Żaneta Dębicka, and Marta Gawlik. "Antineoplastic agents and the use of personal protective equipment: nursing staff awareness." Medical Science Pulse 13, no. 4 (2020): 1–20. http://dx.doi.org/10.5604/01.3001.0014.1208.

Full text

Abstract:

Introduction. Along with an increasing number of cancer patients, the need for cytostatic drugs is also increasing. Nursing staff are the largest professional group exposed to the potential dangers of these substances. Aim of the study. Assess the awareness of nursing staff who have direct contact with cytostatic drugs in the use of personal protective equipment (PPE). Material and methods. The research group consisted of 101 nurses routinely exposed to cytostatic drugs. A diagnostic survey and questionnaire technique were used along with the author’s original questionnaire. Results. Of the re

APA, Harvard, Vancouver, ISO, and other styles

24

Koepf-Maier, Petra, and Hartmut Koepf. "Non-platinum group metal antitumor agents. History, current status, and perspectives." Chemical Reviews 87, no. 5 (1987): 1137–52. http://dx.doi.org/10.1021/cr00081a012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Malacrida, Alessio, Cristina Meregalli, Virginia Rodriguez-Menendez, and Gabriella Nicolini. "Chemotherapy-Induced Peripheral Neuropathy and Changes in Cytoskeleton." International Journal of Molecular Sciences 20, no. 9 (2019): 2287. http://dx.doi.org/10.3390/ijms20092287.

Full text

Abstract:

Despite the different antineoplastic mechanisms of action, peripheral neurotoxicity induced by all chemotherapy drugs (anti-tubulin agents, platinum compounds, proteasome inhibitors, thalidomide) is associated with neuron morphological changes ascribable to cytoskeleton modifications. The “dying back” degeneration of distal terminals (sensory nerves) of dorsal root ganglia sensory neurons, observed in animal models, in in vitro cultures and biopsies of patients is the most evident hallmark of the perturbation of the cytoskeleton. On the other hand, in highly polarized cells like neurons, the c

APA, Harvard, Vancouver, ISO, and other styles

26

Multhaupt, T. P., and S. K. Aggarwal. "Novel Second Generation Platinum Containing Antineoplastic Agents Ssp, Sap, and Poly-Plat and Their Effect on Glucose 6 Phosphate Dehydrogenase (Ec 1.1.1.49) in the Liver and Kidney of Male Wistar Rats." Microscopy and Microanalysis 3, S2 (1997): 57–58. http://dx.doi.org/10.1017/s1431927600007170.

Full text

Abstract:

Poly-(trans-l,2-diaminocyclohexane) platinumj-carboxyamylose (Poly-Plat); 5-SuIfosalicylato-trans-(l,2-diaminocyclohexane) platinum (SSP); and 4-Hydroxy-a-sulfonylphenylacetato (trans 1,2-diaminocyclohexane) platinum (II) (SAP) (Andrulis Pharmaceuticals, Bethesda, MD) are three novel second generation platinum containing antineoplastic compounds. Initial studies indicate that these agents are more effective in the treatment of cancer while at the same time less toxic to the organism as a whole than cisplatin (CDDP). The present study was undertaken to examine the effects of these new compounds

APA, Harvard, Vancouver, ISO, and other styles

27

Floyd, Justin D., Duc T. Nguyen, Raymond L. Lobins, Qaiser Bashir, Donald C. Doll, and Michael C. Perry. "Cardiotoxicity of Cancer Therapy." Journal of Clinical Oncology 23, no. 30 (2005): 7685–96. http://dx.doi.org/10.1200/jco.2005.08.789.

Full text

Abstract:

Because cancer is a leading cause of mortality in the United States, the number of therapeutic modalities available for the treatment of neoplastic processes has increased. This has resulted in a large number of patients being exposed to a wide variety of cancer therapy. Historically, it has been well recognized that antineoplastic agents may have adverse effects on multiple organs and normal tissues. The most commonly associated toxicities occur in tissues composed of rapidly dividing cells and may spontaneously reverse with minimal long-term toxicity. However, the myocardium consists of cell

APA, Harvard, Vancouver, ISO, and other styles

28

Vijayakumar, Jayanthi, Jeffrey Jackson, Kwang W. Ahn, and Parameswaran N. Hari. "Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma." Blood 124, no. 21 (2014): 4771. http://dx.doi.org/10.1182/blood.v124.21.4771.4771.

Full text

Abstract:

Abstract Introduction: Asymptomatic or smoldering multiple myeloma (SMM) is usually 10-15% of all patients with multiple myeloma. Currently, national guidelines do not recommend early treatment of SMM though the majority of patients progress to active disease over time. Multiple trials have been conducted to evaluate implications of early therapy for SMM. Some of these trials, most notably, Mateos et al. (N Engl J Med 2013; 369:438-447) have shown benefit for treating SMM. However, there is lack of consensus as to whether early treatment of SMM prior to symptomatic disease progression is super

APA, Harvard, Vancouver, ISO, and other styles

29

Pelletier, Karyne, Marko Škrtić, and Abhijat Kitchlu. "Cancer therapy-induced hyponatremia: A case-illustrated review." Journal of Onco-Nephrology 5, no. 1 (2021): 70–78. http://dx.doi.org/10.1177/23993693211002216.

Full text

Abstract:

Hyponatremia is the most common electrolyte disorder in patients with cancer and is associated with significant morbidity and mortality. Innovation in cancer therapies has led to substantial improvement in cancer outcomes, but also to new therapy-related toxicities, including electrolyte disturbance. Improvement in clinicians understanding of hyponatremia may mitigate adverse outcomes and improve quality of life in cancer patients. In this case-illustrated review, we discuss the mechanisms underlying drug-induced hyponatremia both in “classical” antineoplastic drugs and novel cancer therapies.

APA, Harvard, Vancouver, ISO, and other styles

30

Haque, Ashanul, Md Ataur Rahman, Md Serajul Haque Faizi, and Muhammad S. Khan. "Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues." Current Medicinal Chemistry 25, no. 14 (2018): 1650–62. http://dx.doi.org/10.2174/0929867324666170502123639.

Full text

Abstract:

Background: Throughout the history of human civilizations, cancer has been a major health problem. Despite the advancements made by modern medical sciences, complete treatment or removal of cancerous cells is still a challenging task. Vinblastine, an alkaloid obtained from Catharanthus roseus (L.) G. Don is one of the prominent antineoplastic agents that is being clinically used. To improve the biological potential and reduce sideeffects of this structurally complex molecule, several related analogues have been reported. The present article reviews recently reported structurally modified vinbl

APA, Harvard, Vancouver, ISO, and other styles

31

Momekov, Georgi, Adriana Bakalova, and Margarita Karaivanova. "Novel Approaches Towards Development of Non-Classical Platinum-Based Antineoplastic Agents: Design of Platinum Complexes Characterized by an Alternative DNA-Binding Pattern and/or Tumor-Targeted Cytotoxicity." Current Medicinal Chemistry 12, no. 19 (2005): 2177–91. http://dx.doi.org/10.2174/0929867054864877.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ruggiero, Antonio, Giovanna Trombatore, Silvia Triarico, et al. "Cisplatin Toxicity in Children with Malignancy." Biomedical and Pharmacology Journal 12, no. 04 (2019): 1603–11. http://dx.doi.org/10.13005/bpj/1791.

Full text

Abstract:

Platinum’ derivates are antineoplastic agents widely adopted for their efficacy for the treatment of many pediatric cancers. The use of cisplatin has positively influenced the results of the cure of different childhood malignancies. However, cisplatin-based treatments are limited by the risk of severe and progressive toxicities, such as oto- or nephrotoxicity, that can be more serious in very young children expecially when high cumulative doses and/or radiotherapy is administered. A correct knowledge of the cisplatin’ pharmacological features might be of interest for clinicians in order to man

APA, Harvard, Vancouver, ISO, and other styles

33

Maulana, Ilham Maulana Ilham, Peter Loennecke Peter Loennecke, and Evamarie Hey-Hawkins Evamarie Hawkins. "Platinum Metal Complexes of Carbaboranylphophines: Potential Anti Cancer Agents." Indonesian Journal of Cancer Chemoprevention 1, no. 1 (2010): 1. http://dx.doi.org/10.14499/indonesianjcanchemoprev1iss1pp1-11.

Full text

Abstract:

Polyhedral heteroboranes in particular dicarba-closo-dodecaboranes(12) and their organic derivatives have been the subject of intense research for over 40 years due to their unique chemical and physical properties. The initial attraction to dicarba-closo-dodecaboranes(12) In the medicinal chemistry research, was a result of their high boron content and stability to catabolism, which are important criteria for cancer therapy, such as BNCT (boron neutron capture therapy) agents. The coordination compounds of the platinum group metals have also received large interest for their potential applicat

APA, Harvard, Vancouver, ISO, and other styles

34

Visacri, Marília Berlofa, Cinthia Madeira de Souza, Rafaela Pimentel, et al. "Pharmacovigilance in oncology: pattern of spontaneous notifications, incidence of adverse drug reactions and under-reporting." Brazilian Journal of Pharmaceutical Sciences 50, no. 2 (2014): 411–22. http://dx.doi.org/10.1590/s1984-82502014000200021.

Full text

Abstract:

The high toxicity and narrow therapeutic window of antineoplastic agents makes pharmacovigilance studies essential in oncology. The objectives of the current study were to analyze the pattern of spontaneous notifications of adverse drug reactions (ADRs) in oncology patients and to analyze the incidence of ADRs reported by outpatients on antineoplastic treatment in a tertiary care teaching hospital. To compose the pattern of ADR, the notification forms of reactions in oncology patients in 2010 were reviewed, and the reactions were classified based on the drug involved, mechanism, causality, and

APA, Harvard, Vancouver, ISO, and other styles

35

Kulyova, Svetlana A., Tatiana Yu Semiglazova, Daria A. Zvyagintseva, Margarita B. Belogurova, Svetlana V. Ivanova, and Irina V. Okisheva. "Cardiovascular complications of antineoplastic therapy in children." Pediatrician (St. Petersburg) 8, no. 3 (2017): 130–41. http://dx.doi.org/10.17816/ped83130-141.

Full text

Abstract:

The improvement of long-term survival in children with malignant tumors is noted in the last five decades. Serious late consequences of the applied therapy including early death, the second tumors, different organ dysfunctions (heart, gonads, liver, lungs) began to come to light with increase in number of cured and follow-up. The article discusses the emergence of cardiotoxicity in children treated with cytostatic and radiation therapy for malignant tumors. Particular attention is paid to the influence of anthracycline antibiotics on the state of the heart muscle. Anthracycline and similar med

APA, Harvard, Vancouver, ISO, and other styles

36

Długosz-Pokorska, Angelika, Joanna Drogosz, Marlena Pięta, et al. "New Uracil Analogs with Exocyclic Methylidene Group as Potential Anticancer Agents." Anti-Cancer Agents in Medicinal Chemistry 20, no. 3 (2020): 359–68. http://dx.doi.org/10.2174/1871520619666191211104128.

Full text

Abstract:

Background: Hybrid molecules combining uracil skeleton with methylidene exo-cyclic group were designed in the search for novel anticancer drug candidates. Objective: Two series of racemic 5-methylidenedihydrouracils, either 1,3-disubstituted or 1,3,6-trisubstituted were synthesized and tested for their possible cytotoxic activity against two cancer cell lines (HL-60 and MCF-7) and two healthy cell lines (HUVEC and MCF-10A). The most cytotoxic analogs were re-synthesized as pure enantiomers. The analog designated as U-332 [(R)-3-(4-bromophenyl)-1-ethyl-5-methylidene-6-phenyldihydrouracil], whic

APA, Harvard, Vancouver, ISO, and other styles

37

Li, Zhen-Yu, Zhen Zhang, Xiao-Zhong Cao, Yun Feng, and Sha-Sha Ren. "Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis." Journal of International Medical Research 48, no. 10 (2020): 030006052096434. http://dx.doi.org/10.1177/0300060520964340.

Full text

Abstract:

Background Triple-negative breast cancer (TNBC) is associated with higher aggressiveness and mortality than hormone-positive breast cancer because of the lack of approved therapeutic targets. Patients with TNBC who attain a pathological complete response (pCR) after neoadjuvant chemotherapy have improved survival. Platinum-based agents show promising activity in TNBC; however, their use remains controversial. We conducted a meta-analysis to assess the role of platinum-based agents in neoadjuvant chemotherapy in patients with TNBC. Methods We performed an extensive literature search of the Pubm

APA, Harvard, Vancouver, ISO, and other styles

38

Jurisevic, Milena, Gordana Radosavljevic, Aleksandar Arsenijevic, et al. "Platinum Complexes with Edda (Ethylenediamine -N, N - Diacetate) Ligands as Potential Anticancer Agents." Serbian Journal of Experimental and Clinical Research 17, no. 4 (2016): 285–96. http://dx.doi.org/10.1515/sjecr-2016-0042.

Full text

Abstract:

Abstract The design of platinum based drugs is not a new field of interest. Platinum complexes are widely used as anticancer agents and currently, approximately 30 platinum(II) and platinum(IV) entered into some of the phases of clinical trials. A special place in today’s research belongs to platinum complexes with diammine ligands. A large number of edda (ethylenediamine- N, N’-diacetate)-type ligands and their corresponding metal complexes has been successfully synthesized. This article summarizes recent progress in research on edda-type-platinum complexes. Some of these agents achieves bett

APA, Harvard, Vancouver, ISO, and other styles

39

Batista de Carvalho, A. L. M., S. F. Parker, L. A. E. Batista de Carvalho, and M. P. M. Marques. "Novel platinum-based anticancer drug: a complete vibrational study." Acta Crystallographica Section C Structural Chemistry 74, no. 5 (2018): 628–34. http://dx.doi.org/10.1107/s2053229618005843.

Full text

Abstract:

The introduction of cisplatin to oncology, in the 1970s, marked the onset of the search for novel and improved metal-based anticancer drugs. Polynuclear PtII and PdII complexes with linear alkylamines as bridging ligands are a class of potential antineoplastic agents that have shown promising cytotoxicity against low-prognosis human cancers, such as metastatic breast adenocarcinoma and osteosarcoma. The present study reports an analysis of [μ-N,N′-bis(3-aminopropyl)butane-1,4-diamine-κ4 N,N′:N′′,N′′′]bis[dichloridoplatinum(II)], [Pt2Cl4(C10H26N4)], denoted Pt2Spm (Spm is spermine), by vibratio

APA, Harvard, Vancouver, ISO, and other styles

40

Aldubayan, Maha A., Rehab M. Elgharabawy, Amira S. Ahmed, and Ehab Tousson. "Antineoplastic Activity and Curative Role of Avenanthramides against the Growth of Ehrlich Solid Tumors in Mice." Oxidative Medicine and Cellular Longevity 2019 (January 13, 2019): 1–12. http://dx.doi.org/10.1155/2019/5162687.

Full text

Abstract:

Interest is growing in finding natural sources of effective antitumor agents that generate fewer side effects than conventional chemotherapeutic drugs. Avenanthramides (Avns) are such compounds; these phenolic molecules naturally occur in oats and have antioxidant, anti-inflammatory, and antiproliferative effects making them worthy of further research. The aim of this study is to characterise Avns’ curative ability and antineoplastic activity on solid-form Ehrlich tumors. For the study, 75 female mice were randomly and equally allocated to five groups (group 1-control, group 2-DMSO, group 3-po

APA, Harvard, Vancouver, ISO, and other styles

41

Jordan, Berit, Franziska Jahn, Sandra Sauer, and Karin Jordan. "Prevention and Management of Chemotherapy-Induced Polyneuropathy." Breast Care 14, no. 2 (2019): 79–84. http://dx.doi.org/10.1159/000499599.

Full text

Abstract:

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a severe and common side effect caused by a variety of antineoplastic agents. Approximately 30–40% of patients treated with agents such as taxanes, vinca alkaloids, or platinum derivatives will develop CIPN. CIPN presents predominantly as a sensory axonal neuro(no)pathy with occasional motor and autonomic dysfunction exhibiting considerable variability of clinical symptoms ranging from mild tingling sensation to severe neuropathic pain. Typical symptoms include numbness (“minus symptom”), weakness, and abnormal gait as well as paresthesia

APA, Harvard, Vancouver, ISO, and other styles

42

Vermorken, J. B. "The role of anthracyclines in second-line therapy of ovarian cancer." International Journal of Gynecologic Cancer 13, Suppl 2 (2003): 178–84. http://dx.doi.org/10.1136/ijgc-00009577-200311001-00009.

Full text

Abstract:

Anthracyclines (ANTs) have been in clinical practice since the 1960s and represent one of the most commonly used classes of anticancer drugs. In the 1990s, meta-analyses showed a favorable impact of doxorubicin (DOX/A) on the survival of patients with advanced ovarian cancer, when it was combined with cyclophosphamide and cisplatin (CAP) and compared to CP alone. With the acceptance of paclitaxel-carboplatin (TCb) as the new reference arm for first-line treatment, testing the addition of ANTs to TCb seems a logic next step. Trials presently testing this, make use of either epirubicin (EPI) or

APA, Harvard, Vancouver, ISO, and other styles

43

Momekov, Georgi, Dilyan Ferdinandov, Spiro Konstantinov, et al. "In Vitro Evaluation of a Stable Monomeric Gold(II) Complex with Hematoporphyrin IX: Cytotoxicity against Tumor and Kidney Cells, Cellular Accumulation, and Induction of Apoptosis." Bioinorganic Chemistry and Applications 2008 (2008): 1–8. http://dx.doi.org/10.1155/2008/367471.

Full text

Abstract:

The antineoplastic potential of a stable monomeric Au(II) complex with hematoporphyrin IX (Hp), namely [Au(II)Hp-2H.(H2O)2], was investigated in a panel of tumor cell lines. The complex exhibits strong cytotoxicity, whereby the leukaemia- and lymphoma-derived cell lines are more sensitive, withIC50values comparable to those of the reference anticancer drug cisplatin. In contrast, the solid tumor models are more sensitive to the platinum drug. A comparative assessment of both agents against the human kidney cell line 293T has shown that [Au(II)Hp-2H.(H2O)2] is less cytotoxic. The gold complex i

APA, Harvard, Vancouver, ISO, and other styles

44

Yoo, Jeongsoo, and Youngkyu Do. "Synthesis of stable platinum complexes containing carborane in a carrier group for potential BNCT agents." Dalton Transactions, no. 25 (2009): 4978. http://dx.doi.org/10.1039/b823193a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Das, Swagatika, H. Inci Gul, Umashankar Das, Jan Balzarini, Stephen G. Dimmock, and Jonathan R. Dimmock. "Novel Conjugated Unsaturated Ketones with Submicromolar Potencies Towards some Leukemic and Colon Cancer Cells." Medicinal Chemistry 15, no. 4 (2019): 430–38. http://dx.doi.org/10.2174/1573406414666181015142633.

Full text

Abstract:

Background: Cancer continues to be the major health burden worldwide. There is an urgent need for the development of novel antineoplastic compounds to treat this devastating condition. Various alkylating anticancer drugs have been employed in the clinic for treating cancers. Unsaturated conjugated ketones are a group of alkylators which are of significant interest as potent antineoplastic agents. Objective: The goal of this study is to discover unsaturated conjugated ketones which are novel potent cytotoxins displaying growth-inhibitory properties towards neoplasms and also to serve as cytotox

APA, Harvard, Vancouver, ISO, and other styles

46

Fracasso, Paula M., John A. Blessing, Mark A. Morgan, Anil K. Sood, and James S. Hoffman. "Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group Study." Journal of Clinical Oncology 21, no. 15 (2003): 2856–59. http://dx.doi.org/10.1200/jco.2003.03.077.

Full text

Abstract:

Purpose: A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with platinum-resistant or refractory epithelial ovarian carcinoma. Materials and Methods: Eligible patients were to receive oxaliplatin 130 mg/m2 intravenously over 2 hours, every 21 days, until progression of disease or adverse effects prohibited further therapy. Results: Of 25 patients entered onto the study, 23 were eligible and assessable. There were no patients with complete response. One patient (4.3%) achieved a partial response, with a response duration of 6.4 months. Nine patients (39

APA, Harvard, Vancouver, ISO, and other styles

47

Möller, Angela, and Gerd Meyer. "The ammonium ion and the ammine ligand as internal reducing agents for platinum-group-metal complexes." Thermochimica Acta 210 (November 1992): 147–50. http://dx.doi.org/10.1016/0040-6031(92)80284-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Chalupczok, Sebastian, Peter Kurzweil, and Helmut Hartmann. "Impact of Various Acids and Bases on the Voltammetric Response of Platinum Group Metal Oxides." International Journal of Electrochemistry 2018 (2018): 1–6. http://dx.doi.org/10.1155/2018/1697956.

Full text

Abstract:

The voltammetric response of platinum metal oxides is discussed with respect to novel pH sensors combining both miniaturization and stability. For practical applications in solutions of any kind, for example, in tap water and in domestic sewage, various interferences must be considered, such as chloride and reducing agents. This work clarifies the voltammetric behavior of RuO2 electrodes in solutions of different pH values and ionic strengths.

APA, Harvard, Vancouver, ISO, and other styles

49

Hochster, Howard, Elizabeth R. Plimack, Carolyn D. Runowicz, et al. "Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group." Journal of Clinical Oncology 22, no. 1 (2004): 120–26. http://dx.doi.org/10.1200/jco.2004.03.016.

Full text

Abstract:

Purpose To determine the antitumor activity of the novel topoisomerase I inhibitor 9-aminocamptothecin (9-AC) given over 72 hours every 2 weeks in patients with ovarian carcinoma previously treated with one platinum-containing regimen. Patients and Methods Patients with ovarian carcinoma who received one prior platinum-containing regimen were eligible. Patients were stratified based on whether their disease was measurable, or nonmeasurable but assessable. 9-AC 35 μg/m2/h was administered by continuous infusion for 72 hours every 2 weeks via ambulatory pump. Results Sixty patients were entered,

APA, Harvard, Vancouver, ISO, and other styles

50

Takano, M., T. Sugiyama, N. Yaegashi, et al. "Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study." International Journal of Gynecologic Cancer 18, no. 5 (2008): 937–42. http://dx.doi.org/10.1111/j.1525-1438.2007.01158.x.

Full text

Abstract:

Clear cell carcinoma (CCC) of the ovary has been recognized to show resistance to anticancer agents in the first-line chemotherapy. Our aim was to evaluate the effect of second-line chemotherapy in a retrospective study. A total of 75 patients diagnosed with CCC and treated between 1992 and 2002 in collaborating hospitals were reviewed. Criteria for the patients' enrollment were 1) diagnosis of pure-type CCC at the initial operation, 2) treatment after one systemic postoperative chemotherapy, 3) measurable recurrent or refractory tumor, 4) at least two cycles of second-line chemotherapy and as

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!